Tolerability of prolonged-release metformin (Glucophage® SR) in individuals intolerant to standard metformin - Results from four UK centres

British Journal of Diabetes and Vascular Disease

Volumn 7, Issue 5, 2007, Pages 225-228

  Feher, Michael D ^a   Al Mrayat, Ma'en ^b   Brake, Julie ^c   Leong, King Sun ^d  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^d CLATTERBRIDGE HOSPITAL   (United Kingdom)

Author keywords

Metformin; Prolonged release metformin; Tolerability; Type 2 diabetes

Indexed keywords

GLUCOPHAGE SR; METFORMIN; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; SUSTAINED RELEASE FORMULATION; UNITED KINGDOM;

EID: 35848970300     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514070070050501     Document Type: Article

References (13)

1. McIntosh A, Hutchinson A, Home PD et al. Clinical guidelines and evidence review for Type 2 diabetes: management of blood glucose. Sheffield: ScHARR, University of Sheffield (2001). Available at www.nice.org.uk. Accessed September 2007.
2. Clinical Guidelines Task Force, International Diabetes Federation. 2005 Global Guideline for Type 2 Diabetes. Available at www.idf.org. Accessed September 2007.
3. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49:1711-21.
4. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.
5. Garber AJ, Larsen J, Schneider SH, Piper BA, Henry D. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab 2002;4:201-8.
6. Davidson JA, Scheen AJ, Howlett HC. Tolerability profile of metformin/ glibenclamide combination tablets (Glucovance): a new treatment for the management of type, 2 diabetes mellitus. Drug Saf 2004; 27:1205-16.
7. Ramsdell JW, Grossman JA, Stephens JM, Botteman MF, Arocho R. A short-term cost-of-treatment model for type 2 diabetes: comparison of glipizide gastrointestinal therapeutic system, metformin, and acarbose. Am J Manag Care 1999;5:1007-24.
8. Scarpello JHB. Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetes. Br J Diabetes Vasc Dis 2001;1:28-36.
9. Howlett H, Davidson J. New prolonged-release metformin improves gastrointestinal tolerability. Br J Diabetes Vasc Dis 2004; 4:273-7.
10. Timmins P, Donahue S, Meeker J, Marathe R Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin Pharmacokinet 2005;44:721-9.
11. Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin 2004;20:565-72.
12. Bailey CJ, Feher MD. Therapies for diabetes. Birmingham. Sherborne Gibbs Ltd, 2004;127.
13. Fujioka K, Pans M, Joyal S. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation. Clin Ther 2003; 25:515-29.